Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults: potential for limiting the death toll during and beyond the COVID-19 pandemic

Brenner, Hermann; Holleczek, Bernd; Schoettker, Ben

doi:10.1101/2020.06.22.20137299

Cited by 18 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(27) In a cohort of 9548 patients followed over 15 years, mortality from respiratory disease was twofold higher in those with 25(OH)D levels <20 ng/mL and threefold higher with levels <12 ng/mL. (28) However, prospective studies of supplementation have yielded conflicting results. The New Zealand Vitamin D Assessment (ViDA) study (n = 5111) that used a monthly bolus dose of 100,000 IU found no benefit for respiratory infections over 3 years even for those with baseline deficiency <20 ng/ mL.…”

Section: Effects Of Vitamin D Dosing On Acute Respiratory Infections and Coronavirus Disease 2019mentioning

confidence: 99%

Vitamin D: Bolus Is Bogus—A Narrative Review

2021

View full text Add to dashboard Cite

In this review we summarize the impact of bolus versus daily dosing of vitamin D on 25(OH)D and 1,25(OH) 2 D levels, as well as on key countervailing factors that block vitamin D functions at the cellular level. Further, we discuss the role of bolus versus daily dosing of vitamin D for several health outcomes, including respiratory infections and coronavirus disease 2019 (COVID-19), rickets, falls and fractures, any cancer, and cancer-related mortality. This discussion appears timely because bolus doses continue to be tested for various disease outcomes despite a growing amount of evidence suggesting lack of efficacy or even detrimental effects of bolus dosing of vitamin D for outcomes where daily dosing at modest levels was effective in the vitamin D deficient. As a result, these discordant results may bias health recommendations for vitamin D if the recommendations are based on meta-analyses combining both daily and bolus dosing trials.

show abstract

Section: Effects Of Vitamin D Dosing On Acute Respiratory Infections and Coronavirus Disease 2019mentioning

confidence: 99%

Vitamin D: Bolus Is Bogus—A Narrative Review

2021

View full text Add to dashboard Cite

show abstract

“…33 Vitamin D deficiency could be associated with adverse outcomes in COVID-19. 34,35 In our study, nearly 70% of patients had vitamin D levels below 30 ng/mL. Dram e et al published a systematic review that suggests an association between vitamin D deficiency and risk of COVID-19 in aged people.…”

Section: Discussionmentioning

confidence: 48%

COVID-19 versus Seasonal Influenza: Comparison of Profiles of Older Adults Hospitalized in a Short-Term Geriatric Ward in France

Godaert

Cebille

Proye

et al. 2022

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

The objective was to compare the profile and outcomes of older adults admitted to a geriatric short-stay unit for COVID-19, to those of older adults admitted to the same unit for seasonal influenza infection. This was an observational study performed in a General Hospital in France. Patients ≥ 70 years admitted to a geriatric short-stay unit for COVID-19 between March 18 and November 15, 2020 were included. They were compared with patients of the same age group, admitted to the same geriatric short-stay unit for seasonal influenza infection over the periods January to March 2019 and January to March 2020. Data collection included demographic information, medical history, clinical signs and symptoms, outcomes, and hospital discharge patterns. Descriptive and intergroup comparison analyses were performed. In total, 153 patients were included in the study, 82 in the seasonal influenza group, and 71 in the COVID-19 group. The average age was 87.6 ± 4.8 and 87.6 ± 6.5 years in the COVID-19 and seasonal influenza groups, respectively. There was no difference between groups regarding the Charlson comorbidity index (3.4 ± 3.0 versus 3.4 ± 2.8). The seasonal influenza group more often had fever, cough, sputum, and renal failure, whereas the COVID-19 group more often experienced diarrhea, and death. The COVID-19 group was frequently living in collective housing. The profile at admission of older adults hospitalized for COVID-19 or seasonal influenza infection was similar. Although fever and respiratory signs were less common in the COVID-19 group, these patients experienced more complications (such as renal failure or oxygen therapy requirement) and higher mortality.

show abstract

“…At the same time, VIT-D may modify the risk of respiratory tract infections (RTIs). [5][6][7][8] The UK Scientific Advisory on Nutrition (SCAN), in a revision of its previous conclusion, 9 has suggested that low dose VIT-D supplementation between 10 µg (400 IU) and 25 µg (1000 IU) may be of some benefit in reducing the risk of acute respiratory tract infection (ARTI). 10 Because of this, VIT-D has increasingly been explored in the context of COVID-19 infections.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D in the time of the coronavirus (COVID-19) pandemic – a clinical review from a public health and public mental health perspective

Werneke

Gaughran

Taylor

2021

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Individuals with serious mental disorders (SMD) may have a higher risk of vitamin D (VIT-D) deficiency. They also experience higher mortality because of coronavirus disease 2019 (COVID-19) infection. Therefore, we have conducted a comprehensive review to examine the significance of VIT-D for public health and public mental health during the ongoing COVID-19 pandemic. This review had three specific aims, from a global perspective to (a) create a profile of VIT-D and review the epidemiology of VIT-D deficiency, (b) explore VIT-D deficiency as risk factor for SMD and COVID-19 infections and (c) examine the effectiveness of VIT-D supplementation for both conditions. We found that, in terms of SMD, the evidence from laboratory and observational studies points towards some association between VIT-D deficiency and depression or schizophrenia. Mendelian randomisation studies, however, suggest no, or reverse, causality. The evidence from intervention studies is conflicting. Concerning COVID-19 infection, on proof of principle, VIT-D could provide a plausible defence against the infection itself and against an adverse clinical course. But data from observational studies and the first preliminary intervention studies remain conflicting, with stronger evidence that VIT-D may mitigate the clinical course of COVID-19 infection rather than the risk of infection in the first place. From a public health and public mental health point of view, based on the currently limited knowledge, for individuals with SMD, the benefits of VIT-D optimisation through supplementation seem to outweigh the risks. VIT-D supplementation, however, should not substitute for vaccination or medical care for COVID-19 infection.

show abstract

Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults: potential for limiting the death toll during and beyond the COVID-19 pandemic

Cited by 18 publications

References 27 publications

Vitamin D: Bolus Is Bogus—A Narrative Review

Vitamin D: Bolus Is Bogus—A Narrative Review

COVID-19 versus Seasonal Influenza: Comparison of Profiles of Older Adults Hospitalized in a Short-Term Geriatric Ward in France

Vitamin D in the time of the coronavirus (COVID-19) pandemic – a clinical review from a public health and public mental health perspective

Contact Info

Product

Resources

About